BACKGROUND: HCV exposure among blood donors is serologically determined by detection of antibodies to HCV (anti-HCV); however, the recent development of an assay for the detection of HCV core antigen identifies infection before anti-HCV development. Simultaneous detection of HCV core antigen and anti-HCV would shorten the window period before seroconversion over conventional HCV antibody screening assays. STUDY DESIGN AND METHODS: A prototype chemiluminescent immunoassay was developed for simultaneous detection of HCV core antigen and anti-HCV in human sera and plasma. The assay was performed on a single-channel instrument representing an automated serologic analyzer (PRISM, Abbott Laboratories) system. Sensitivity and specificity were evaluated by testing 23 HCV seroconversion panels and plasma or sera from volunteer blood donors. RESULTS: The prototype HCV core antigen and antibody combination assay detected 80 of 89 (89.9% ) HCV RNA-positive and antibody-negative specimens from 23 panels, thereby reducing the seroconversion window period by an average of 34.3 days compared to PRISM HCV antibody detection. All PRISM HCV antibody-positive specimens were detected by the combination assay for a relative sensitivity of 100 percent. The repeatedly reactive rate was 0.20 percent based on testing of 3017 screened anti-HCV-negative sera and plasma. CONCLUSIONS: The prototype combination assay was shown to detect HCV core antigen and anti-HCV simultaneously and significantly closed the time gap between the initial detection of HCV RNA and the first appearance of detectable antibodies to HCV.
T ests for antibodies against the HCV have been used for the detection of HCV infection since 1989. 1 The incidence of posttransfusion HCV has declined steadily since the implementation of routine screening of whole blood and plasma for HCV antibodies. 2, 3 The HCV second-and third-generation HCV antibody tests have improved detection of individuals infected with all known viral genotypes and have shown earlier detection of seroconversion than the first-generation assays. However, the average window period between HCV infection and seroconversion with new generation of HCV antibody tests remains approximately 70 days. 2 To prevent transmission of HCV during the window period before seroconversion, NAT for HCV has been developed. Its implementation in many developed countries has dramatically reduced the residual risk for posttransfusional HCV infection.
Recent studies indicate that HCV core antigen can be detected in the window period before seroconversion, and HCV core antigen levels correlate well with HCV RNA levels. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] We recently reported on the development of a new HCV core antigen detection assay developed for an automated chemiluminescent analyzer. 9 The antigen assay showed excellent specificity (>99%) and sensitivity relative to NAT of 98.6 percent based on testing of 15 HCV seroconversion panels. Development and implementation of an assay combining the detection of HCV core antigen and anti-HCV into a single test would shorten the HCV detection window significantly and improve the safety of blood supply over the current HCV antibody test. In this report we describe the development and performance against seroconversion panels of an HCV assay capable of simultaneous detection of HCV core antigen and anti-HCV.
MATERIALS AND METHODS

HCV core antigen and antibody assay (combination assay)
A high-throughput, fully automated serologic analyzer (PRISM, Abbott Laboratories, Abbott Park, IL) was used to screen plasma or sera for antibodies and or antigens associated with exposure to transfusion-transmitted viruses. 14 The prototype combination assay uses a two-step assay protocol similar to the current PRISM HCV antibody assay. The assay format is illustrated in Fig. 1 . At the first step, the instrument dispenses 100 mL of sample, 50 mL of specimen diluent buffer, and 50 mL of blended HCV recombinant antigen-coated microparticles and MoAb anti-HCV core-coated microparticles in the sample well of a reaction tray. The blended microparticles are capable of capturing both HCV core antigen and antibodies to HCV in the same reaction well. After 20 minutes at 37°C, the tray is moved to the transfer station where the reaction mixture in the sample-well is flushed by a transfer wash buffer into the reaction well where microparticles are captured on a filter while excessive fluid is absorbed by an underlying blotter. At the second step, 50 mL of conjugate is dispensed to the reaction well to tag analytes captured on microparticles in the reaction well. After 25 minutes at 37°C, microparticles are washed with a conjugate wash buffer to remove unbound conjugates into the blotter. The reaction well is moved to the reading station where an alkaline hydrogen peroxide is dispensed to trigger chemiluminescence from the acridinium-labeled conjugates captured in the reaction well. The core antigen present in human sera or plasma specimens is detected by a second anti-core MoAb labeled with acridinium. Antibodies present in human serum or plasma HCV recognizing recombinant antigens coated on microparticles are detected by a second antibody directed against human IgG and labeled with acridinium. The intensity of chemiluminescent signal in relative light unit is proportional to the amount of HCV core antigen and anti-HCV in the sample. The total assay time is under 1 hour.
Assay reagents
Solid-phase. The HCV core antigen and antibody combination assay uses a blend of two kinds of microparticles including microparticles coated with MoAbs to HCV core antigen and microparticles coated with HCV recombinant antigens representing amino acid sequences from core, NS3, and NS4 gene products of HCV. The recombinant antigens were constructed specifically to avoid the epitope recognition by the MoAbs to HCV core antigen. The selection of MoAbs was based on epitope mapping and detection for all genotypes and possible mutants.
Conjugate. The combination assay uses a blend of two acridinium-labeled conjugates: 1) acridinium-labeled anti-HCV core MoAb and 2) acridinium-labeled MoAb anti-human IgG. 10-(3-Sulfopropyl)-N-tosyl-N-(2-carboxyethyl)-9-acridinium carboxamide was used to pre-SHAH ET AL. pare the conjugates via N-hydroxysuccinimide ester in a phosphate or borate buffer. For signal amplification, the conjugate of anti-HCV core MoAb was prepared by linking BSA labeled with multiple acridinium molecules to the MoAb anti-HCV core via a hetero-bifunctional process. After conjugation, the conjugate was purified by sizeexclusion HPLC. The acridinium-to-protein molar ratio of the conjugate was determined spectrophotometrically by measuring at 370 and 280 nm. Controls. Negative calibrator was recalcified normal human plasma testing negative for HBsAg and antibodies to HCV, HIV, HTLV, and HBc. The HCV-positive calibrator of the current PRISM HCV antibody assay was used as the HCV antibody-positive control to assure the HCV antibody detection by the combination assay. HCV core antigen-positive plasma, JV017220, was purchased from SeroTec Inc. (Raleigh, NC) and diluted for HCV core antigen-control to assess the HCV core antigen detectability. This plasma has HCV RNA at 14 million copies per mL as determined by a HCV RNA quantitative assay (LCx, Abbott Laboratories) 9 and tested highly positive with an HCV core antigen EIA, but tested negative with current HCV antibody assays. The limit of quantification for the LCx HCV RNA assay is 25 IU per mL (100 copies/mL); this compares to 600 IU per mL for one assay (Monitor, Roche, Indianapolis, IN) and 615 IU per mL for another thirdgeneration RNA assay (Versant, Bayer Corp., Pittsburgh, PA).
TRANSFUSION
10
HCV seroconversion panels
Twenty-three HCV seroconversion panels were purchased from BCP (Impath/BioClinical Partners, Franklin, MA), BBI (Boston Biomedica, Inc., West Bridgewater, MA), and NABI (North America Biological Inc., Boca Raton, FL). All panels were tested with the prototype PRISM HCV combination assay and PRISM HCV antibody assay. The genotypes of each panel and HCV RNA in each bleed of 21 panels were determined with the LCx HCV RNA quantitative assay as previously described. 9 RNA titers for the remaining two panels (BBI PHV917 and BCP6215) were supplied by the vendors.
Volunteer blood donors
A total of 3017 specimens including EDTA plasma and sera were obtained from Gulf Coast Regional Blood Center (Houston, TX) and ProMedDx (Norton, MA). The unlinked specimens were collected from randomly selected donors and were screened with a third-generation HCV ELISA (Ortho-Clinical Diagnostics, Rochester, NY) or a secondgeneration HCV EIA (Abbott Laboratories) as negative for antibodies to HCV; all specimens were negative for HCV RNA after minipool testing by the blood bank (Amplicor [F. Hoffman-LaRoche Ltd., Basel, Switzerland] or TMA test [Gen-Probe, San Diego, CA]). All specimens were tested within 7 days from collection with the combination assay. The HCV PRISM combination assay results obtained were used to determine a provisional cutoff for the assay.
RESULTS
Assay specificity
A total of 3017 screened human sera and plasma samples from random volunteer blood donor specimens were tested for the presence of HCV core antigen and anti-HCV by use of the prototype HCV combination assay. A provisional cutoff calculation was set that minimized the number of repeatedly reactive specimens among the screened negative volunteer blood donors and maximized the number of HCV core antigen and antibody combinationpositive bleeds from all HCV seroconversion panels. The provisional cutoff value was set at three times the average mean relative light unit of the negative calibrator which is tested in quadruplicate during each run. Samples with signal-to-cutoff ratio (S/CO) values equal to or greater than 1.0 were considered initial reactive, and samples with S/CO values below 1.0 were considered negative. However, those samples with S/CO values between 0.80 and 0.99, were considered initial "gray zone"-reactive. All initial reactive and initial gray zone-reactive specimens were retested in duplicate. Using the preliminary cutoff for the HCV combination assay, six repeatedly reactive specimens were identified with S/CO values between 1.0 and 2.1 among the 3017 screened donor samples. All six repeat-reactive samples were RIBA-negative. Therefore, the nonconfirming repeatedly reactive rate was 0.20 percent resulting in an apparent specificity of 99.8 percent. A representative histogram of population distribution by prototype combination assay is shown in Fig. 2 .
HCV seroconversion panel testing
A total of 23 commercially available HCV seroconversion panels were tested by the HCV combination assay. The serologic profiles for three representative panels are shown in Fig. 3 The seroconversion panels were segregated into two sets. The first set consisted of eight panels in which the first bleed tested negative for HCV RNA and HCV antibody. Among these panels, the HCV combination assay detected exposure before HCV seroconversion in all eight panels and detected the infection on the same day as HCV RNA in six of the eight panels (Table 1) . For one panel (BCP6213), HCV RNA detected two bleeds ahead of the HCV combination assay and seven bleeds ahead of the anti-HCV assay. For panel BCP9054, HCV RNA detection preceded the HCV combination assay in one bleed and the anti-HCV assay in three bleeds for HCV detection. In total, the HCV combination assay detected 36 of 39 (92.3%) specimens that were HCV RNA-positive and negative for anti-HCV, thus reducing the window period before seroconversion by an average of 34.3 days. The HCV RNA assay detected exposure to HCV an average of 3.6 days earlier than the HCV combination assay.
The second set of seroconversion panels consisted of those whose first bleed was HCV RNA-positive. Among these panels, the HCV combination assay detected exposure before HCV seroconversion in 12 of the 15 panels (Table 2) . HCV RNA detection preceded detection by both the HCV combination and the antibody assays in three panels (BCP6212, SC0010, and PHV908). In these three panels, positive results were obtained by the HCV combination assay and the antibody assay on the same bleed date. The HCV combination assay detected a total of 44 of 50 (88%) HCV RNA-positive and antibody-negative specimens resulting in a reduction in the window period before seroconversion by an average of 14.4 days. The HCV RNA 1a  140  140  182  0  42  10  10  2  BCP6213  1a  11  18  43  7  25  7  5  3  BCP6222  1a  17  17  40  0  23  5  5  4  BCP6225  1a  45  45  78  0  33  6  6  5  BCP6227  1a  42  42  74  0  32  2  2  6  BCP9041  1a  24  24  62  0  38  3  3  7  BCP9054  3a  52  74  82  22  8  3  2  8  PHV917  2b  13  13  86  0  73  3 The combination assay had a repeatedly reactive rate of 0.20 percent or an apparent specificity of 99.8 percent based on testing of 3017 specimens of screened HCVnegative sera and plasma samples. The specificity may be decreased to less than 99.8 percent upon testing of unscreened specimens. However, the six nonconfirming repeat-reactive samples had low S/CO values, and the specificity will be improved with further optimization.
The data indicate that the HCV combination assay has a definite advantage over existing antibody screening assays by virtue of its ability to detect HCV infection much earlier. There are several ways to assess the sensitivity of the HCV combination test. One method is to determine the number of days of earlier detection of infection with HCV, compared to HCV antibody testing and HCV NAT. Among seroconversion panels that begin with members that are HCV RNA-negative and anti-HCV-negative, the HCV combination test detected 36 of 39 (92.3%) HCV RNA-positive and anti-HCV-negative specimens (Table 1) . Thus, the HCV combination test detected exposure to HCV an average of 34.3 days earlier than HCV antibody detection and was 3.6 days later than HCV NAT. For the second set of seroconversion panels composed of members that begin with an HCV RNA-positive samples, 
DISCUSSION
The prototype PRISM HCV core antigen and antibody combination assay was shown to detect HCV core antigen and anti-HCV simultaneously. A total of 23 commercially available seroconversion panels, including subtypes 1a, 1b, 2b, and 3a, were tested by the combination assay. Similar to the HCV core antigen assay, the combination assay positivity paralleled detection of panel members in the window period before seroconversion that were HCV RNA-positive, as depicted by the profiles of the panels in Fig. 3 . Thus, the sensitivity of HCV core antigen detection in the combination format was similar to that of the "HCV antigen-only" PRISM assay.
the HCV combination test detected 44 of 50 (88%) HCV RNA-positive and anti-HCV-negative specimens (Table 2) . For these panels, the window period before seroconversion was reduced by an average of 14.4 days by utilizing the HCV combination assay, but 1.9 days later than HCV NAT. The mean window-period reductions between these two sets of seroconversion panels are significantly different. This is due to the fact that the second set of preseroconversion data starts after infection with HCV has already occurred, thus reducing the number of available samples in the window period before seroconversion. A second method to determine the sensitivity of the HCV core antigen and antibody combination assay is to determine the detection rate among specimens that are HCV RNA-positive and anti-HCV-negative. Among the total of 23 seroconversion panels, the combination assay was able to detect 80 of 89 (89.9%) of the HCV RNApositive anti-HCV-negative members tested (Tables 1 and  2 ). Thus, one would expect that employing an HCV combination test would detect approximately 90 percent of the blood donations obtained during the window period before seroconversion. In other words, the window period before seroconversion can be reduced by nearly 90 percent when the HCV combination assay is utilized as an alternative to NAT. This translates to a "residual risk" of 1 per 1.31 million donations by the combination assay compared to 1 per 1.46 million donations by NAT. 15 However, two bleeds among these seroconversion panels in Table 1 had HCV RNA at 933 and 1380 copies per mL, one each in panel BCP6213 and BCP9054, respectively. Specimens with such low levels of HCV RNA might be missed in minipool with NAT; then, the difference between the HCV combination test and NAT for HCV detection would be further reduced.
Recent data showed that significant numbers of samples were anti-HCV-positive but NAT-negative when tested in minipool. 16, 17 Several of the later bleeds in seroconversion panel PHV917 tested negative for HCV RNA but tested positive in the HCV antibody assay and the HCV combination assay. It should be recognized that the level of virus declines and fluctuates widely in patients after seroconversion or during remission and chemotherapy. 18 Specimens from these patients may transiently test negative for viral nucleic acid or viral antigen but may still be infectious despite the presence of HCV antibodies. For example, approximately 30 percent of anti-HCV-positive donors in Australia have no detectable HCV RNA. 19 Hence, NAT will supplement immunoassays rather than replace them.
Although the prototype HCV combination assay provides earlier detection of exposure to HCV compared to HCV antibody testing, HCV NAT provides even earlier detection than is afforded by the HCV combination assay. Based on the test results of the limited number of samples around the cutoff, the combination assay is estimated to detect HCV core antigen in samples with HCV RNA titers at as low as 107,152 copies per mL (Table 3) . It is possible that further improvements in the HCV combination test will allow the assay to approach the sensitivity of NAT; further optimization of the HCV combination assay is in progress to enhance its HCV core antigen detection capability and to reduce the nonconfirming repeatedly reactive rate. However, in its current form, the HCV core antigen and antibody combination assay reduced the remaining window period before seroconversion by approximately 90 percent, a significant achievement for an assay that does not rely on nucleic acid amplification to detect HCV infection. NAT is expensive, time-consuming, laborintensive, and not affordable in many countries compared to the advantage offered by the HCV combination assay as a possible alternative.
